Methyl-donor supplementation in obese mice prevents the progression of NAFLD, activates AMPK and decreases acyl-carnitine levels

Molecular Metabolism

Volumn 3, Issue 5, 2014, Pages 565-580

  Dahlhoff, Christoph ^a   Worsch, Stefanie ^a   Sailer, Manuela ^a   Hummel, Björn A ^b   Fiamoncini, Jarlei ^a   Uebel, Kirsten ^a   Obeid, Rima ^b   Scherling, Christian ^a   Geisel, Jürgen ^b   Bader, Bernhard L ^a   Daniel, Hannelore ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Acyl carnitines; AMP activated protein kinase; Hepatic steatosis; Obesity; One carbon metabolism; oxidation

Indexed keywords

3 HYDROXYBUTYRATE DEHYDROGENASE; ACYLCARNITINE; CARNITINE; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHOLIPID; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; SERINE; UNCLASSIFIED DRUG;

ACYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FATTY ACID OXIDATION; FATTY LIVER; GENE EXPRESSION; GROWTH INHIBITION; LIPID DIET; LIPID STORAGE; MALE; METABOLITE; METHYL DONOR SUPPLEMENTATION; METHYLATION; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT FAILURE;

MUS;

EID: 84904297835     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2014.04.010     Document Type: Article

References (66)

1. Starley B.Q., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51:1820-1832.
2. Lazo M., Clark J.M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Seminars in Liver Disease 2008, 28:339-350.
3. Wree A., Kahraman A., Gerken G., Canbay A. Obesity affects the liver- the link between adipocytes and hepatocytes. Digestion 2011, 83:124-133.
4. Varela-Rey M., Embade N., Ariz U., Lu S.C., Mato J.M., Martinez-Chantar M.L. Non-alcoholic steatohepatitis and animal models: understanding the human disease. International Journal of Biochemistry & Cell Biology 2009, 41:969-976.
5. Angulo P. Nonalcoholic fatty liver disease. New England Journal of Medicine 2002, 346:1221-1231.
6. Musso G., Gambino R., Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Progress in Lipid Research 2009, 48:1-26.
7. Rinella M.E., Elias M.S., Smolak R.R., Fu T., Borensztajn J., Green R.M. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. Journal of Lipid Research 2008, 49:1068-1076.
8. Lu S.C., Alvarez L., Huang Z.Z., Chen L., An W., Corrales F.J., et al. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:5560-5565.
9. Martinez-Chantar M.L., Vazquez-Chantada M., Ariz U., Martinez N., Varela M., Luka Z., et al. Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 2008, 47:1191-1199.
10. Walkey C.J., Yu L., Agellon L.B., Vance D.E. Biochemical and evolutionary significance of phospholipid methylation. Journal of Biological Chemistry 1998, 273:27043-27046.
11. Noga A.A., Vance D.E. Agender-specific role for phosphatidylethanolamine N-methyltransferase-derived phosphatidylcholine in the regulation of plasma high density and very low density lipoproteins in mice. Journal of Biological Chemistry 2003, 278:21851-21859.
12. Zhao Y., Su B., Jacobs R.L., Kennedy B., Francis G.A., Waddington E., et al. Lack of phosphatidylethanolamine N-methyltransferase alters plasma VLDL phospholipids and attenuates atherosclerosis in mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2009, 29:1349-1355.
13. Williams K.T., Schalinske K.L. Homocysteine metabolism and its relation to health and disease. Biofactors 2010, 36:19-24.
14. Finkelstein J.D. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine. Clinical Chemistry and Laboratory Medicine 2007, 45:1694-1699.
15. Mato J.M., Martinez-Chantar M.L., Lu S.C. Methionine metabolism and liver disease. Annual Review of Nutrition 2008, 28:273-293.
16. Ball C.R. Actions of betaine, carnitine and choline on the pattern of hepatic liposis in mice fed a high-fat, low-protein diet. Anatomical Record 1964, 149:677-689.
17. Ji C., Kaplowitz N. Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology 2003, 124:1488-1499.
18. Powell C.L., Bradford B.U., Craig C.P., Tsuchiya M., Uehara T., O'Connell T.M., et al. Mechanism for prevention of alcohol-induced liver injury by dietary methyl donors. Toxicological Sciences 2010, 115:131-139.
19. Kharbanda K.K., Mailliard M.E., Baldwin C.R., Beckenhauer H.C., Sorrell M.F., Tuma D.J. Betaine attenuates alcoholic steatosis by restoring phosphatidylcholine generation via the phosphatidylethanolamine methyltransferase pathway. Journal of Hepatology 2007, 46:314-321.
20. Song Z., Deaciuc I., Zhou Z., Song M., Chen T., Hill D., et al. Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. American Journal of Physiology - Gastrointestinal and Liver Physiology 2007, 293:G894-G902.
21. Kwon D.Y., Jung Y.S., Kim S.J., Park H.K., Park J.H., Kim Y.C. Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. Journal of Nutrition 2009, 139:63-68.
22. Wang Z., Yao T., Pini M., Zhou Z., Fantuzzi G., Song Z. Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease. American Journal of Physiology - Gastrointestinal and Liver Physiology 2010, 298:G634-G642.
23. Kathirvel E., Morgan K., Nandgiri G., Sandoval B.C., Caudill M.A., Bottiglieri T., et al. Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. American Journal of Physiology - Gastrointestinal and Liver Physiology 2010, 299:G1068-G1077.
24. Wolff G.L., Kodell R.L., Moore S.R., Cooney C.A. Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice. FASEB Journal 1998, 12:949-957.
25. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
26. Pfaffl M.W., Tichopad A., Prgomet C., Neuvians T.P. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper - Excel-based tool using pair-wise correlations. Biotechnology Letters 2004, 26:509-515.
27. Rubio-Aliaga I., Roos B., Sailer M., McLoughlin G.A., Boekschoten M.V., van Erk M., et al. Alterations in hepatic one-carbon metabolism and related pathways following a high-fat dietary intervention. Physiological Genomics 2011, 43:408-416.
28. Kirsch S.H., Knapp J.P., Geisel J., Herrmann W., Obeid R. Simultaneous quantification of S-adenosyl methionine and S-adenosyl homocysteine in human plasma by stable-isotope dilution ultra performance liquid chromatography tandem mass spectrometry. Journal of Chromatography B - Analytical Technologies in the Biomedical and Life Sciences 2009, 877:3865-3870.
29. Stabler S.P., Lindenbaum J., Savage D.G., Allen R.H. Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 1993, 81:3404-3413.
30. Römisch-Margl W., Prehn C., Bogumil R., Röhring C., Suhre C., Adamski J. Procedure for tissue sample preparation and metabolite extraction for high-throughput targeted metabolomics. Metabolomics 2011, 8:113-142.
31. Molero J.C., Waring S.G., Cooper A., Turner N., Laybutt R., Cooney G.J., et al. Casitas b-lineage lymphoma-deficient mice are protected against high-fat diet-induced obesity and insulin resistance. Diabetes 2006, 55:708-715.
32. R-Development-Core-Team R: a language and environment for statistical computing 2009, R Foundation for Statistical Computing, Vienna, Austria.
33. Smyth G.K. Limma: linear models for microarray data. Bioinformatics and computational biology solutions using R and bioconductor 2005, 397-420.
34. Harrell F.J. Hmisc: Harrell Miscellaneous. R package version 3.7-0 2009.
35. Browning J.D., Horton J.D. Molecular mediators of hepatic steatosis and liver injury. Journal of Clinical Investigation 2004, 114:147-152.
36. Hardie D.G. AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. Biochemical Society Transactions 2011, 39:1-13.
37. Ruderman N., Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nature Reviews Drug Discovery 2004, 3:340-351.
38. Weltman M.D., Farrell G.C., Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996, 111:1645-1653.
39. Pooya S., Blaise S., Moreno Garcia M., Giudicelli J., Alberto J.M., Gueant-Rodriguez R.M., et al. Methyl donor deficiency impairs fatty acid oxidation through PGC-1alpha hypomethylation and decreased ER-alpha, ERR-alpha, and HNF-4alpha in the rat liver. Journal of Hepatology 2012, 57:344-351.
40. Desmarchelier C., Dahlhoff C., Keller S., Sailer M., Jahreis G., Daniel H. C57Bl/6N mice on a Western diet display reduced intestinal and hepatic cholesterol levels despite a plasma hypercholesterolemia. BMC Genomics 2012, 13:84.
41. Mihalik S.J., Goodpaster B.H., Kelley D.E., Chace D.H., Vockley J., Toledo F.G., et al. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 2009, 18:1695-1700.
42. Muoio D.M., Newgard C.B. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nature Reviews Molecular Cell Biology 2008, 9:193-205.
43. Vanni E., Bugianesi E., Kotronen A., De Minicis S., Yki-Jarvinen H., Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa?. Digestive and Liver Disease 2010, 42:320-330.
44. Park E.I., Garrow T.A. Interaction between dietary methionine and methyl donor intake on rat liver betaine-homocysteine methyltransferase gene expression and organization of the human gene. Journal of Biological Chemistry 1999, 274:7816-7824.
45. Finkelstein J.D., Martin J.J., Harris B.J., Kyle W.E. Regulation of hepatic betaine-homocysteine methyltransferase by dietary betaine. Journal of Nutrition 1983, 113:519-521.
46. Park E., Renduchintala M.S., Garrow T. Diet-induced changes in hepatic betaine-homocysteine methyltransferase activity are mediated by changes in the steady-state level of its mRNA. Nutritional Biochemistry 1997, 8:541-545.
47. Teng Y.W., Mehedint M.G., Garrow T.A., Zeisel S.H. Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas. Journal of Biological Chemistry 2011, 286:36258-36267.
48. ter Veld F., Primassin S., Hoffmann L., Mayatepek E., Spiekerkoetter U. Corresponding increase in long-chain acyl-CoA and acylcarnitine after exercise in muscle from VLCAD mice. Journal of Lipid Research 2009, 50:1556-1562.
49. Faergeman N.J., Knudsen J. Role of long-chain fatty acyl-CoA esters in the regulation of metabolism and in cell signalling. Biochemical Journal 1997, 323(Pt 1):1-12.
50. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nature Reviews Molecular Cell Biology 2012, 13:251-262.
51. Jager S., Handschin C., St-Pierre J., Spiegelman B.M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:12017-12022.
52. Teyssier C., Ma H., Emter R., Kralli A., Stallcup M.R. Activation of nuclear receptor coactivator PGC-1alpha by arginine methylation. Genes & Development 2005, 19:1466-1473.
53. Garcia M.M., Gueant-Rodriguez R.M., Pooya S., Brachet P., Alberto J.M., Jeannesson E., et al. Methyl donor deficiency induces cardiomyopathy through altered methylation/acetylation of PGC-1alpha by PRMT1 and SIRT1. Journal of Pathology 2011, 225:324-335.
54. Li S., Arning E., Liu C., Vitvitsky V., Hernandez C., Banerjee R., et al. Regulation of homocysteine homeostasis through the transcriptional coactivator PGC-1alpha. American Journal of Physiology - Endocrinology and Metabolism 2009, 296:E543-E548.
55. Ingebritsen T.S., Lee H.S., Parker R.A., Gibson D.M. Reversible modulation of the activities of both liver microsomal hydroxymethylglutaryl coenzyme A reductase and its inactivating enzyme. Evidence for regulation by phosphorylation-dephosphorylation. Biochemical and Biophysical Research Communications 1978, 81:1268-1277.
56. Hawley S.A., Davison M., Woods A., Davies S.P., Beri R.K., Carling D., et al. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. Journal of Biological Chemistry 1996, 271:27879-27887.
57. Lucas M., Encinar J.A., Arribas E.A., Oyenarte I., Garcia I.G., Kortazar D., et al. Binding of S-methyl-5'-thioadenosine and S-adenosyl-L-methionine to protein MJ0100 triggers an open-to-closed conformational change in its CBS motif pair. Journal of Molecular Biology 2010, 396:800-820.
58. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine 2002, 8:1288-1295.
59. Finkelstein J.D. Methionine metabolism in mammals. Journal of Nutritional Biochemistry 1990, 1:228-237.
60. De La Haba G., Cantoni G.L. The enzymatic synthesis of S-adenosyl-L-homocysteine from adenosine and homocysteine. Journal of Biological Chemistry 1959, 234:603-608.
61. Boison D., Scheurer L., Zumsteg V., Rulicke T., Litynski P., Fowler B., et al. Neonatal hepatic steatosis by disruption of the adenosine kinase gene. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:6985-6990.
62. Martinez-Chantar M.L., Vazquez-Chantada M., Garnacho M., Latasa M.U., Varela-Rey M., Dotor J., et al. S-adenosylmethionine regulates cytoplasmic HuR via AMP-activated kinase. Gastroenterology 2006, 131:223-232.
63. Ogborn M.R., Nitschmann E., Bankovic-Calic N., Buist R., Peeling J. Dietary betaine modifies hepatic metabolism but not renal injury in rat polycystic kidney disease. American Journal of Physiology - Gastrointestinal and Liver Physiology 2000, 279:G1162-G1168.
64. Vaz F.M., Wanders R.J. Carnitine biosynthesis in mammals. Biochemical Journal 2002, 361:417-429.
65. Van Hove J.L., Zhang W., Kahler S.G., Roe C.R., Chen Y.T., Terada N., et al. Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: diagnosis by acylcarnitine analysis in blood. American Journal of Human Genetics 1993, 52:958-966.
66. Orellana-Gavalda J.M., Herrero L., Malandrino M.I., Paneda A., Sol Rodriguez-Pena M., Petry H., et al. Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation. Hepatology 2011, 53:821-832.